January 29, 2020

Barriers to Cancer Clinical Trial Enrollment in Early Adolescents and Young Adults

Even when cancer clinical trials are available, fewer eAYAs than children enroll

650×450-Teen-Cancer

Significantly fewer early adolescents and young adults (eAYAs; ages 15–21) enroll in cancer clinical trials (CCTs) than children, according to a study in Cancer, although there are equal proportions of CCTs available to both age groups. This could be one reason why there have been significant improvements in the survival of pediatric and older adult patients with cancer that have not been seen in the eAYA population.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“We’re at a point at which scientific discoveries are happening very quickly,” states Stefanie Thomas, MD, a pediatric oncologist at Cleveland Clinic Children’s. “Looking at CCT participation in this population is important because their cancers are often rare diseases. We need more patients enrolled in CCTs to move science forward at a rate at which the findings would be relevant. In order to accomplish that, we need studies like this that give us insight into enrollment rates, and specifically, factors that might influence enrollment.”

Published in 2018, the study assesses rates of clinical trial enrollment in a group of pediatric and AYA cancer patients seeking care at the Children’s Hospital of Los Angeles (CHLA). Dr. Thomas, first author on the study, is a Cleveland native and Cleveland Clinic Children’s alumnus who completed a post-fellowship in AYA oncology at CHLA and the University of Southern California (USC) before returning to Cleveland Clinic Children’s.

Cancer clinical trial enrollment

In this study, researchers examined clinical trial existence, which they defined as a nationally registered CCT that was appropriate for the patient’s age, diagnosis and stage/risk group, and listed as open and recruiting on ClinicalTrials.gov. Then, according to Dr. Thomas, the team asked if that trial was available locally at CHLA, and whether or not the patient enrolled.

Patients (216) were included if they presented with a new primary cancer diagnosis in a 13-month period. In total, there were 58 eAYA patients and 158 children included. Patient demographics (i.e., age, sex, race/ethnicity) and disease-related data (i.e., cancer diagnosis, stage, grade, risk group and relevant genomics) were extracted from medical records for analysis.

Advertisement

Analysis revealed similar proportions of CCTs existed and were available for children and eAYAs. However, the 15–21 year olds did not enroll as frequently. Specifically, among those patients with existing and available CCTs, only 30.4% of eAYAs enrolled compared with 67.7% of children.

In terms of predictors of CCT enrollment, patients were less likely to enroll if they were in the eAYA age group. Patients with solid tumors and male patients were also less likely to enroll.

Trial existence and availability are not barriers

Overall, the results confirm a significant enrollment gap, and suggest that CCT existence and availability are not barriers to enrollment as once thought.

“With this project, we sought to look prospectively at each individual patient to see what the trial landscape looked like at that particular time. It was really a deep dive into understanding this enrollment problem,” continues Dr. Thomas. “We were actually pretty surprised by this finding. Lack of trial availability at children’s hospitals is frequently cited as a reason for low CCT enrollment. We expected our results to confirm this supposition. It was surprising that even when a trial is available, these adolescents did not agree to participate in a trial.”

Advertisement

Next steps

Dr. Thomas is currently assembling baseline CCT enrollment data for Cleveland Clinic Children’s, and hopes to develop interventions that can be implemented to address eAYA trial participation at the institution.

“At Cleveland Clinic, there’s a great relationship between the pediatric and adult oncology services,” says Dr. Thomas. “It’s unique to have these services under the same umbrella, and this collaboration may help increase CCT enrollment among eAYAs with cancer and aid in care transitions.”

More globally, Dr. Thomas believes a paradigm shift is needed to increase eAYA enrollment in clinical trials. In her opinion, efforts should be made to bring studies to patients at their treating hospitals rather than asking them to disrupt their lives to travel for CCTs. Additionally, she believes change is needed in the way that these studies are offered to patients to ensure comprehension.

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad